Legal

Pfizer Settles 2 Lawsuits, Starts Another Over Etanercept Biosimilar in Australia

May 16th 2022

By Skylar Jeremias

After agreeing to settle with Amgen over its oncology biosimilars, Pfizer issued a new patent lawsuit against 5 companies over the development of Brenzys, an etanercept biosimilar, in Australia.

The US Is Entering Round 2 of Biosimilar Activity, Says Cardinal Health’s Oskouei

May 3rd 2022

By Laura Joszt

Article

The United States is about to enter round 2 of biosimilar activity with a pipeline that expands biosimilars into new therapeutic areas, said Sonia Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars, Cardinal Health, during her presentation at Asembia’s Specialty Pharmacy Summit.

Jeffrey Casberg Discusses the Alvotech, AbbVie Settlement Over an Adalimumab Biosimilar

April 27th 2022

By Skylar Jeremias

Video

Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discusses the Alvotech/AbbVie settlement for an adalimumab biosimilar and whether it will impact future patent lawsuits.

AbbVie Settles ITC Case With Alvotech; Humira Biosimilar to Launch July 2023

March 8th 2022

By Skylar Jeremias

Article

AbbVie settles outstanding lawsuits, including its case related to the International Trade Commission (ITC), with Alvotech, giving Alvotech the green light to launch its high-concentration, citrate-free adalimumab biosimilar referencing Humira in July 2023, pending FDA approval.

In Iceland, Switch to Adalimumab Biosimilar Reveals Issues With Injection Device

February 15th 2022

By Mary Caffrey

Article

Iceland’s national health plan required patients to switch from Humira to the Samsung Bioepis biosimilar, Imraldi, which had a different injection device and contained citrate, a chemical buffer used to maintain the medication’s stability.

A 2021 Recap of Biosimilars: Approvals, Legislation, and What’s to Come

February 14th 2022

By Skylar Jeremias

Article

The year 2021 proved to be big for biosimilars, with 4 approvals and increased competition, signaling that FDA is shifting some of their focus from the pandemic back to the growing industry.

IGBA Launches Panel of 13 CEO-Level Advisers

February 7th 2022

By The Center for Biosimilars

Article

The IGBA maintains dialogue with other national, regional, and international bodies to ensure patient access to high-quality, safe, and effective medicines while reducing costs in pharmaceutical care.

AmerisourceBergen Rep Previews the Year Ahead for Biosimilars: What’s Coming Down the Pipeline in 2022?

January 24th 2022

By Tony Hagen

Video

Sean McGowan, senior director of Biosimilars for AmerisourceBergen, forecasts potential biosimilar approvals and launches in 2022 as well as offers insights into how emerging biosimilars will impact the market and pricing in the coming years during an interview.

International Biosimilars Trade Group Appoints New Leadership for 2022

January 15th 2022

By Tony Hagen

Article

The International Generic and Biosimilar Medicines Association has appointed a veteran member, Vivian Frittelli, MBA, ACIS, to take over as chair.

Amgen CEO Touts Potential for Doubling in Biosimilar Revenue

January 11th 2022

By Tony Hagen

Article

Amgen Chairman and CEO Robert Bradway touted the potential of 11 biosimilars anticipated to be driving revenues for the company by 2030.